YORK, Pa. — A simple cheek swab claims to give patients an individualized look at which medications are best suited for their mental health, based on their DNA. "There may be an issue where ...

The combinatorial, multi-gene GeneSight test has been found to better predict antidepressant treatment outcomes for patients with depression, and their use of health care resources, than any of the ...

SALT LAKE CITY, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, announced today the peer-reviewed journal Psychiatry Research ...

Myriad Genetics, Inc. announced that a study published in the Journal of Clinical Psychopharmacology found that the GeneSight® Psychotropic Test significantly reduced psychiatric hospitalizations in ...

SALT LAKE CITY, Sept. 3, 2025 – Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced the publication of a new meta-analysis of six ...

SALT LAKE CITY, June 08, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today a newly published study in Psychiatry ...

SALT LAKE CITY, July 12, 2022 (GLOBE NEWSWIRE) -- Major Depressive Disorder (MDD) remission rates were significantly improved when clinicians had access to GeneSight ® Psychotropic test results from ...

Myriad Genetics, Inc., a leader in molecular diagnostic testing and precision medicine, today announced a post-hoc analysis of the Precision Medicine in Mental Health Care (PRIME) study showed that ...

“For three years, it was like throwing darts at a dartboard – except, I was the dartboard,” said Ronni, whose acute suffering persisted as she and her health care providers searched for medication to ...

FARGO – Nichole Mortice has struggled for all of her 37 years with anger and depression. She attempted suicide several times as a child and adolescent. She tried to hang herself, overdose on ...